|
|
Caspian Journal of Internal Medicine، جلد ۷، شماره ۲، صفحات ۱۰۵-۱۱۳
|
|
|
| عنوان فارسی |
|
|
| چکیده فارسی مقاله |
|
|
| کلیدواژه‌های فارسی مقاله |
|
|
| عنوان انگلیسی |
The acute lymphoblastic leukemia prognostic scoring whether it is possible by BCL-2, BAX gene promoter genotyping |
|
| چکیده انگلیسی مقاله |
Background: BCL-2 is the most important anti-apoptotic regulator and Bax is a pro-apoptotic protein. The status of these parameters or the ration of BCL-2 to BAX is important in malignant cell fate as well as normal cells. Methods: Sixty-two ALL patients and 62 healthy sex-and age-matched controls were studied. After genotyping, the promoter region of the BAX and BCL-2 genes by RFLP-PCR method the patients were classified in nine prognostic groups, after that, the overall survival ratio of each score was compared with others pair-wise or between groups. Results: The frequencies of the AA, AC, CC alleles of the BCL-2 C-938A polymorphism in patient group were 33 (53.23%), 18 (29.03%), 11 (17.74%), and in the control group were 13 (21.0%), 27 (43.5%), 22 (35.5%), respectively (P=0.003). Also, the frequencies of AA, AG, GG alleles of the BAX G-248A SNP were 15 (24.2%), 24 (38.7%), 23 (37.1%) in ALL group and 13 (21.0%), 25 (40.3%), 24 (38.7%) (p>0.05) in the control group. The survival time estimation and ratio were significantly different between different SNPs in BCL-2 (P=0.002). Conclusion: These findings showed that the BCL-2 promoter region polymorphism is more reliable than BAX gene promoter polymorphism in any ALL scoring system. But the establishment of complete scoring system requires further more clinical and laboratory findings along with genetic polymorphisms is necessary |
|
| کلیدواژه‌های انگلیسی مقاله |
|
|
| نویسندگان مقاله |
مژگان معظمی گودرزی | mozhgan moazami goudarzi
stem cell research center, tabriz university of medical science, tabriz, iran
سازمان اصلی تایید شده: دانشگاه تبریز (Tabriz university)
مجید فرش دوستی حق | majid farshdousti hagh
hematology and oncology research center, tabriz university of medical science, tabriz, iran
سازمان اصلی تایید شده: دانشگاه تبریز (Tabriz university)
عباسعلی حسینپور فیضی | abbasali hoseinpour feizi
hematology and oncology research center, tabriz university of medical science, tabriz, iran
سازمان اصلی تایید شده: دانشگاه تبریز (Tabriz university)
مهدی طالبی | mehdi talebi
hematology and oncology research center, tabriz university of medical science, tabriz, iran
سازمان اصلی تایید شده: دانشگاه تبریز (Tabriz university)
علی اکبر موثق پوراکبری | ali akbar movassaghpour akbari
hematology and oncology research center, tabriz university of medical science, tabriz, iran
سازمان اصلی تایید شده: دانشگاه تبریز (Tabriz university)
کریم شمس اسنجان | karim shams asanjan
hematology and oncology research center, tabriz university of medical science, tabriz, iran
سازمان اصلی تایید شده: دانشگاه تبریز (Tabriz university)
جمال عیوضی ضیایی | jamal eyvazi ziyaee
hematology and oncology research center, tabriz university of medical science, tabriz, iran
سازمان اصلی تایید شده: دانشگاه تبریز (Tabriz university)
مرتضی سیفی | morteza seifi
department of medical genetics, university of alberta, alberta, canada
|
|
| نشانی اینترنتی |
http://www.caspjim.com/browse.php?a_code=A-10-351-1&slc_lang=en&sid=en |
| فایل مقاله |
فایلی برای مقاله ذخیره نشده است |
| کد مقاله (doi) |
|
| زبان مقاله منتشر شده |
en |
| موضوعات مقاله منتشر شده |
Hematology |
| نوع مقاله منتشر شده |
Original Article |
|
|
|
برگشت به:
صفحه اول پایگاه |
نسخه مرتبط |
نشریه مرتبط |
فهرست نشریات
|